Pliant Therapeutics reported positive safety data and antifibrotic effects for 320mg bexotegrast in a Phase 2a clinical trial for primary sclerosing cholangitis patients.

Pliant Therapeutics announced positive safety data for bexotegrast (320 mg) in its Phase 2a clinical trial, INTEGRIS-PSC, for patients with primary sclerosing cholangitis and suspected liver fibrosis. Bexotegrast was well-tolerated over a 12-week treatment period and no severe or serious adverse events were reported. The treatment also showed improvements in hepatocyte function and bile flow. The 320 mg dose cohort demonstrated consistent antifibrotic effects in line with previous findings. The company will host a webcast and conference call to discuss these results further.

February 04, 2024
4 Articles